English-proficient women with a history of stage I, II, or III breast cancer
Free of oncologic disease by clinical examination and history;
Receiving third-generation AI therapy (anastrozole, letrozole, or exemestane) for at least 28 days prior to consent with plan to continue for at least another 12 months;
Worst joint pain rated at least 4 or greater on a 0-10 numeric rating scale in the preceding week prior to consent;
Reporting at least 15 days with pain in the preceding 30 days prior to consent;
Experiencing joint pain for at least one month;
Pain attributed to AI therapy;
Willing to adhere to all study-related procedures, including randomization to one of two treatment arms: Mindfulness-Oriented Recovery Enhancement (MORE) or Supportive Group Psychotherapy (SG);
Able to attend video-call sessions in a quiet/private location.
You may not be if
Metastatic breast cancer (stage IV);
Completed chemotherapy, surgery, or radiation therapy less than 4 weeks prior to enrollment;
Pain attributed to inflammatory arthritis (i.e. rheumatoid arthritis, gout, pseudogout);
Surgery or joint injection involving the affected joints within the last month or planned within the next six months;
Active suicidality or psychosis as determined by the Mini-International Neuropsychiatric Interview.
Clareo Health | Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors
